Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Neuroscience ; 155(3): 948-58, 2008 Aug 26.
Artigo em Inglês | MEDLINE | ID: mdl-18621103

RESUMO

The N-methyl-d-aspartate (NMDA) receptor in the spinal cord dorsal horn (SCDH) is one of the mechanisms involved in central sensitization during chronic pain. Previously, this laboratory created a spatio-temporal knockout (KO) of the N-methyl-d-aspartate receptor I (NR1) subunit in the mouse SCDH. The NR1 KO completely blocks NR1 gene and subsequent NMDA receptor expression and function in SCDH neurons. In the NR1 KO mice, the mechanical and cold allodynia induced at 24 h after complete Freund's adjuvant (CFA) was reduced. However, the protective effects of KO were transient and were not seen at 48 h after CFA. These observations suggest the presence of NMDA-independent pathways that contribute to CFA-induced pain. CFA induces the activation of several signaling cascades in the SCDH, including protein kinase C (PKC)gamma and extracellular signal-regulated kinases (ERK1/2). The phosphorylation of PKCgamma and ERK1/2 was inhibited in the SCDH of NR1 KO mice up to 48 h after CFA treatment, suggesting that these pathways are NMDA receptor-dependent. Interestingly, neuronal cyclooxygenase (COX) -2 expression and microglial p38 phosphorylation were induced in the SCDH of the NR1 KO at 48 h after CFA. Our findings provide evidence that inflammatory reactions are responsible for the recurrence of pain after NR1 KO in the SCDH.


Assuntos
Dor/patologia , Células do Corno Posterior/metabolismo , Receptores de N-Metil-D-Aspartato/deficiência , Transdução de Sinais/fisiologia , Medula Espinal/patologia , Análise de Variância , Animais , Ciclo-Oxigenase 2/metabolismo , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Adjuvante de Freund/efeitos adversos , Regulação Enzimológica da Expressão Gênica , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Hiperalgesia/fisiopatologia , Camundongos , Camundongos Transgênicos , Dor/induzido quimicamente , Limiar da Dor/fisiologia , Fosforilação/efeitos dos fármacos , Estimulação Física , Proteína Quinase C/metabolismo , Transdução de Sinais/efeitos dos fármacos , Fatores de Tempo
2.
Neuroscience ; 232: 182-93, 2013 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-23201828

RESUMO

Dorsal horn neurons send ascending projections to both thalamic nuclei and parabrachial nuclei; these pathways are thought to be critical pathways for central processing of nociceptive information. Afferents from the corneal surface of the eye mediate nociception from this tissue which is susceptible to clinically important pain syndromes. This study examined corneal afferents to the trigeminal dorsal horn and compared inputs to thalamic- and parabrachial-projecting neurons. We used anterograde tracing with cholera toxin B subunit to identify corneal afferent projections to trigeminal dorsal horn, and the retrograde tracer FluoroGold to identify projection neurons. Studies were conducted in adult male Sprague-Dawley rats. Our analysis was conducted at two distinct levels of the trigeminal nucleus caudalis (Vc) which receive corneal afferent projections. We found that corneal afferents project more densely to the rostral pole of Vc than the caudal pole. We also quantified the number of thalamic- and parabrachial-projecting neurons in the regions of Vc that receive corneal afferents. Corneal afferent inputs to both groups of projection neurons were also more abundant in the rostral pole of Vc. Finally, by comparing the frequency of corneal afferent appositions to thalamic- versus parabrachial-projecting neurons, we found that corneal afferents preferentially target parabrachial-projecting neurons in trigeminal dorsal horn. These results suggest that nociceptive pain from the cornea may be primarily mediated by a non-thalamic ascending pathway.


Assuntos
Córnea/anatomia & histologia , Neurônios/citologia , Núcleos Parabraquiais/anatomia & histologia , Núcleos Talâmicos/anatomia & histologia , Núcleo Inferior Caudal do Nervo Trigêmeo/anatomia & histologia , Vias Aferentes/anatomia & histologia , Animais , Toxina da Cólera , Imuno-Histoquímica , Masculino , Microscopia Confocal , Técnicas de Rastreamento Neuroanatômico , Ratos Sprague-Dawley , Estilbamidinas
3.
Neuroscience ; 213: 191-200, 2012 Jun 28.
Artigo em Inglês | MEDLINE | ID: mdl-22521830

RESUMO

The periaqueductal gray (PAG) is part of a descending pain modulatory system that, when activated, produces widespread and profound antinociception. Microinjection of either opioids or cannabinoids into the PAG elicits antinociception. Moreover, microinjection of the cannabinoid 1 (CB1) receptor agonist HU-210 into the PAG enhances the antinociceptive effect of subsequent morphine injections, indicating a direct relationship between these two systems. The objective of this study was to characterize the distribution of CB1 receptors in the dorsolateral and ventrolateral PAG in relationship to mu-opioid peptide (MOP) receptors. Immunocytochemical analysis revealed extensive and diffuse CB1 receptor labeling in the PAG, 60% of which was found in somatodendritic profiles. CB1 and MOP receptor immunolabeling were co-localized in 32% of fluorescent Nissl-stained cells that were analyzed. Eight percent (8%) of PAG neurons that were MOP receptor-immunoreactive (-ir) received CB1 receptor-ir appositions. Ultrastructural analysis confirmed the presence of CB1 receptor-ir somata, dendrites and axon terminals in the PAG. These results indicate that behavioral interactions between cannabinoids and opioids may be the result of cellular adaptations within PAG neurons co-expressing CB1 and MOP receptors.


Assuntos
Neurônios/metabolismo , Neurônios/ultraestrutura , Substância Cinzenta Periaquedutal/metabolismo , Receptor CB1 de Canabinoide/biossíntese , Receptores Opioides mu/biossíntese , Animais , Imuno-Histoquímica , Masculino , Microscopia Confocal , Microscopia Eletrônica de Transmissão , Ratos , Ratos Sprague-Dawley
4.
Neuroscience ; 168(2): 543-50, 2010 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-20394808

RESUMO

Microinjection of opioids into the ventrolateral periaqueductal gray (vlPAG) produces antinociception in part by binding to mu-opioid receptors (MOPrs). Although both high and low efficacy agonists produce antinociception, low efficacy agonists such as morphine produce limited MOPr internalization suggesting that MOPr internalization and signaling leading to antinociception are independent. This hypothesis was tested in awake, behaving rats using DERM-A594, a fluorescently labeled dermorphin analog, and internalization blockers. Microinjection of DERM-A594 into the vlPAG produced both antinociception and internalization of DERM-A594. Administration of the irreversible opioid receptor antagonist beta-chlornaltrexamine (beta-CNA) prior to DERM-A594 microinjection reduced both the antinociceptive effect and the number of DERM-A594 labeled cells demonstrating that both effects are opioid receptor-mediated. Pretreatment with the internalization blockers dynamin dominant-negative inhibitory peptide (dynamin-DN) and concanavalinA (ConA) attenuated both DERM-A594 internalization and antinociception. Microinjection of dynamin-DN and ConA also decreased the antinociceptive potency of the unlabeled opioid agonist dermorphin when microinjected into the vlPAG as demonstrated by rightward shifts in the dose-response curves. In contrast, administration of dynamin-DN had no effect on the antinociceptive effect of microinjecting the GABA(A) receptor antagonist bicuculline into the vlPAG. The finding that dermorphin-induced antinociception is attenuated by blocking receptor internalization indicates that key parts of opioid receptor-mediated signaling depend on internalization.


Assuntos
Analgésicos Opioides/farmacologia , Peptídeos Opioides/farmacologia , Dor/tratamento farmacológico , Receptores Opioides mu/metabolismo , Analgésicos Opioides/química , Analgésicos Opioides/uso terapêutico , Animais , Bicuculina/farmacologia , Concanavalina A/farmacologia , Dinaminas/antagonistas & inibidores , Corantes Fluorescentes/química , Antagonistas de Receptores de GABA-A , Masculino , Microinjeções , Naltrexona/análogos & derivados , Naltrexona/farmacologia , Neurônios/metabolismo , Peptídeos Opioides/química , Peptídeos Opioides/uso terapêutico , Dor/metabolismo , Dor/fisiopatologia , Medição da Dor , Peptídeos/farmacologia , Substância Cinzenta Periaquedutal/efeitos dos fármacos , Substância Cinzenta Periaquedutal/metabolismo , Ratos , Ratos Sprague-Dawley , Receptores Opioides mu/antagonistas & inibidores
5.
BMJ ; 305(6848): 311; author reply 311-2, 1992 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-1285765
6.
Age Ageing ; 24(2): 99-102, 1995 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-7793344

RESUMO

The aims of this study were to document the level of tetanus immunity in elderly people; to assess the value of immunization history in predicting tetanus immune status and to determine the response to tetanus immunization in elderly people compared with younger subjects. One-hundred day-hospital attenders (group 1), 100 long-term-care residents (group 2) and 50 young subjects (group 3) were recruited. Protective titres of tetanus antitoxin antibodies were detected in 20% of group 1, 45% of group 2 and 80% of group 3. Tetanus immunization history was a poor predictor of immune status in older people with a positive predictive value of 50% and a negative predictive value of 76%. The response to tetanus immunization was slower and of lower magnitude in older people. However, 36 of 37 older subjects developed protective levels of tetanus antitoxin antibodies on completion of a primary immunization programme.


Assuntos
Anticorpos Antibacterianos/sangue , Clostridium tetani/imunologia , Avaliação Geriátrica , Toxoide Tetânico/imunologia , Tétano/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Hospital Dia , Feminino , Humanos , Programas de Imunização , Esquemas de Imunização , Assistência de Longa Duração , Masculino , Tétano/prevenção & controle , Toxoide Tetânico/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA